Company news

Share this article:

Par Pharmaceutical reached a settlement and license agreement with Ortho-McNeil Pharmaceutical, ending a patent suit related to the Johnson & Johnson unit's Ultracet acute pain product. Par said it will pay Ortho-McNeil a royalty on sales of its generic tramadol/acetaminophen product through Nov. 15 and will stop selling the product by that date. Par will also pay Ortho- McNeil royalties on sales from August 2006 to June 2007.

Novo Nordisk has filed legal action in the US to block the launch of Sanofi-Aventis' new Solo-Star insulin injection pen, The Financial Times reported. Novo Nordisk is seeking an injunction because it claims Sanofi's Solo-Star pen infringes on the patents on its NovoPen 4. Sanofi-Aventis' Solo-Star injection pen, which administers Lantus insulin, was recently approved by the FDA. Sanofi-Aventis launched Solo-Star in France and Germany in May and has plans to introduce it elsewhere across Europe and in the US in the months ahead.Both insulin pens will be competing in a global insulin market worth up to $8.2 billion. Sanofi-Aventis said in the Financial Times report that it disagreed with Novo Nordisk's claims and would “vigorously defend” its rights.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.